Journal of Cardiovascular and Clinical Medicine, 1(1):10–15, 2026. DOI: 10.58612/jccm112

Journal of Cardiovascular and Clinical Medicine

Journal homepage: https://www.fpub.org/journal-details.php?journal-id=46



Review Article

Risk Assessment and Peri-procedural Optimization in Complex Percutaneous Coronary Intervention: Evidence-Based Strategies for Improved Clinical Outcomes

Xin Liang[1] **and Yiming Sun**[1]

[1]*Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, Anhui, China*
[*]*Corresponding author: lx408643989@126.com*

Article Info

Keywords: *Coronary Intervention, Risk Stratification, Hemodynamic Support Devices.*

Received: *02.06.2026;*
Accepted: *22.06.2026;*
Published: *29.06.2026*

Abstract

Complex percutaneous coronary intervention (PCI) is increasingly performed in patients with advanced coronary artery disease, multiple comorbidities, and high procedural risk, making accurate risk stratification and peri-procedural optimization essential to improving outcomes. Contemporary risk assessment integrates anatomical complexity scores such as the SYNTAX and residual SYNTAX scores with clinical models including GRACE, ACEF, and registry-based prediction tools to guide procedural planning and clinical decision-making. Beyond risk prediction, peri-procedural optimization strategies have evolved to include physiological lesion assessment using fractional flow reserve and instantaneous wave-free ratio, intravascular imaging guidance with intravascular ultrasound and optical coherence tomography, and refined antithrombotic and vascular access strategies to minimize ischemic and bleeding complications. Hemodynamic support devices such as intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation have expanded the therapeutic window for high-risk PCI in patients with impaired ventricular function or cardiogenic shock. Additionally, advances in patient selection, multidisciplinary heart team approaches, and tailored peri-procedural pharmacotherapy have contributed to improved procedural safety and long-term outcomes. Despite these advancements, challenges remain in integrating complex risk models into routine practice and defining optimal strategies for specific high-risk subgroups. This review synthesizes current evidence on risk stratification frameworks and peri-procedural optimization techniques in complex PCI, highlighting emerging tools and future directions to enhance personalized interventional cardiology care and improve patient-centered outcomes.

1. Introduction

Percutaneous coronary intervention (PCI) has transformed the management of coronary artery disease (CAD), offering effective revascularization strategies for patients with both acute and chronic coronary syndromes. Advances in stent technology, pharmacotherapy, and procedural techniques have significantly improved outcomes over the past decades. However, complex PCI—defined by factors such as multivessel disease, chronic total occlusions, left main coronary artery involvement, heavy calcification, and hemodynamic instability—remains associated with substantial procedural risk and long-term adverse cardiovascular events. As the complexity of coronary anatomy and patient comorbidities increases, the need for accurate risk stratification and optimized peri-procedural strategies becomes paramount to improving patient outcomes [1, 2].

How To Cite: X. Liang, and Y. Sun. Risk Assessment and Peri-procedural Optimization in Complex Percutaneous Coronary Intervention: Evidence-Based Strategies for Improved Clinical Outcomes. *Journal of Cardiovascular and Clinical Medicine*, 1(1):10–15, 2026. https://doi.org/10.58612/jccm112

Risk stratification plays a central role in guiding clinical decision-making before PCI. Angiographic and clinical risk models have been developed to predict procedural complexity and long-term outcomes. The SYNTAX score, introduced as an angiographic tool to quantify coronary lesion complexity, remains a cornerstone in assessing anatomical disease burden and guiding revascularization strategies [3]. Subsequent developments such as the clinical SYNTAX score integrated clinical variables with angiographic data to enhance prognostic accuracy, reflecting the multifactorial nature of cardiovascular risk [4]. Further refinements, including SYNTAX-derived models and SYNTAX score II, have been validated for predicting mortality and major adverse cardiovascular events and for guiding decisions between PCI and coronary artery bypass grafting (CABG) [5, 6]. These tools underscore the importance of combining anatomical complexity with clinical risk profiles to achieve individualized patient assessment.

In addition to traditional scoring systems, novel predictive models incorporating multiple clinical and procedural variables are emerging. Contemporary studies have proposed integrated risk score models capable of predicting long-term ischemic outcomes after PCI, highlighting the growing role of precision medicine and data-driven risk prediction in interventional cardiology [7]. Preprocedural evaluation, including assessment of comorbidities, hemodynamic status, and functional significance of coronary lesions, is increasingly recognized as a critical determinant of procedural success and long-term prognosis [8].

Beyond risk assessment, peri-procedural optimization strategies have been shown to significantly influence PCI outcomes. Physiological lesion assessment using fractional flow reserve (FFR) has demonstrated superiority over angiography-guided PCI in multivessel disease, reducing unnecessary interventions and improving clinical outcomes [9]. Antithrombotic strategies, such as the use of bivalirudin during primary PCI, have also contributed to reductions in bleeding complications and improved safety profiles [10]. These procedural innovations highlight the importance of tailored therapeutic approaches during PCI to minimize complications and enhance procedural efficacy.

Hemodynamic support devices represent another critical component of peri-procedural optimization, particularly in high-risk PCI settings. Mechanical circulatory support devices such as intra-aortic balloon pumps and percutaneous ventricular assist devices have been utilized to stabilize patients with cardiogenic shock or severely compromised ventricular function during complex interventions. Evidence suggests that hemodynamic support can facilitate complete revascularization and improve procedural safety in high-risk populations [11, 12]. Recent systematic reviews and meta-analyses have further evaluated outcomes associated with Impella-supported PCI, underscoring the evolving role of advanced hemodynamic support strategies in contemporary practice [13].

Clinical outcomes following PCI are influenced not only by procedural factors but also by broader therapeutic strategies and patient selection. Long-term data from the SYNTAX trial demonstrated differential outcomes between PCI and CABG in complex coronary disease, emphasizing the need for careful revascularization strategy selection based on anatomical and clinical risk profiles [14]. Furthermore, recent meta-analyses comparing PCI with optimal medical therapy in stable CAD have highlighted the importance of individualized treatment decisions and comprehensive risk-benefit assessment [15].

Current guideline recommendations emphasise a patient-centered approach to revascularization, integrating clinical presentation, anatomical complexity, functional assessment, and patient preferences. The 2021 ACC/AHA/SCAI guideline for coronary artery revascularization underscores the importance of multidisciplinary heart team discussions and evidence-based risk stratification to guide revascularization strategies and optimize outcomes [1]. Despite these advancements, significant variability remains in risk prediction accuracy, procedural planning, and peri-procedural management, particularly in patients undergoing complex PCI.

In this context, synthesizing evidence-based approaches to risk stratification and peri-procedural optimization is essential for improving clinical outcomes in complex PCI. Understanding the interplay between anatomical complexity, clinical risk factors, physiological lesion assessment, pharmacologic therapy, and hemodynamic support strategies provides a comprehensive framework for individualized patient care. This review aims to summarize contemporary evidence on risk stratification tools and peri-procedural optimization strategies in complex PCI, highlighting their clinical implications and future directions for improving patient outcomes.

2. Methods

This narrative review was conducted to synthesize contemporary evidence on risk stratification and peri-procedural optimization strategies in complex percutaneous coronary interventions (PCI) and to evaluate their impact on clinical outcomes. A structured literature search and qualitative synthesis approach was employed, integrating clinical guidelines, randomized trials, risk prediction models, and systematic reviews to provide evidence-based insights relevant to clinical practice. The methodological framework and evidence sources included in this review are summarized in Table 1

A comprehensive search of the published literature was undertaken using electronic databases including PubMed, Scopus, Web of Science, and Google Scholar. Search terms included combinations of "complex percutaneous coronary intervention," "high-risk PCI," "risk stratification," "SYNTAX score," "hemodynamic support," "peri-procedural optimization," "fractional flow reserve," "antithrombotic therapy," and "clinical outcomes." Boolean operators and MeSH terms were applied to enhance retrieval sensitivity and specificity. Only articles published in English were considered. Priority was given to studies published within the last two decades, with emphasis on recent guidelines, randomized controlled trials, systematic reviews, and meta-analyses.

Guideline documents from major cardiovascular societies, including the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions, were included to provide standardized recommendations on coronary revascularization and procedural decision-making. The 2021 ACC/AHA/SCAI guideline for coronary artery revascularization served as a foundational reference for procedural indications, patient selection, and peri-procedural management [1]. Additional studies evaluating procedural and nonprocedural determinants of PCI outcomes were reviewed to contextualize the multifactorial nature of procedural success and complications [2].

Risk stratification models were a core focus of the review. The SYNTAX score and its derivatives were included to assess anatomical complexity and guide revascularization strategies. Original and validation studies describing the angiographic SYNTAX score and clinical SYNTAX score were reviewed to highlight their prognostic significance in complex coronary artery disease [3, 4]. Further evidence examining the predictive value of SYNTAX-derived models for adverse cardiovascular outcomes was incorporated, including studies demonstrating the role of these scores in long-term risk prediction [5]. Additional contemporary risk models, including multivariable risk prediction tools developed for PCI populations, were also reviewed to reflect evolving approaches to individualized risk estimation [7]. The SYNTAX score II was included to illustrate combined clinical and anatomical risk modeling for guiding revascularization strategies between

PCI and coronary artery bypass grafting [6].

Table 1: Summary of evidence sources and methodological framework for the narrative review

Category	Description
Study design	Narrative review with structured literature search and qualitative evidence synthesis.
Databases searched	PubMed, Scopus, Web of Science, and Google Scholar.
Search terms	Complex percutaneous coronary intervention, "high-risk PCI," "risk stratification," "SYNTAX score," "hemodynamic support," "peri-procedural optimization," "fractional flow reserve," "fractional flow reserve," "antithrombotic therapy," and "clinical outcomes."
Search strategy	Boolean operators and MeSH terms were used to enhance sensitivity and specificity of retrieval.
Language restriction	English-language publications only.
Time frame of included studies	Primarily studies published within the last two decades, with emphasis on contemporary guidelines, randomized trials, and recent systematic reviews/meta-analyses.
Guideline sources	ACC/AHA/SCAI coronary revascularization guidelines and other major cardiovascular society statements.
Risk stratification tools reviewed	SYNTAX score, Clinical SYNTAX score, SYNTAX score II, multivariable PCI risk prediction models.
Peri-procedural optimization strategies	Mechanical circulatory support (e.g., Impella), FFR-guided PCI, antithrombotic therapy optimization, procedural and nonprocedural outcome modifiers.
Landmark trials included	SYNTAX trial, FAME trial, HORIZONS-AMI trial, and other pivotal PCI studies.
Inclusion criteria	(1) Studies focusing on PCI risk stratification; (2) peri-procedural optimization strategies; (3) clinical outcome reporting; (4) relevance to complex/high-risk PCI populations.
Exclusion criteria	Non-coronary intervention studies, studies without clinical outcome data, and irrelevant observational reports.
Data extraction variables	Study design, population characteristics, risk stratification tools, optimization strategies, and clinical outcomes.
Data synthesis approach	Qualitative narrative synthesis due to heterogeneity of study designs and outcome measures.
Objective of methodological approach	To provide clinically relevant, evidence-based insights for improving procedural success and patient outcomes in complex PCI.

Evidence on peri-procedural optimization strategies was identified and synthesized. Studies addressing the role of mechanical circulatory support in high-risk PCI, including Impella and other hemodynamic support devices, were included to evaluate procedural safety and outcomes in complex cases [11, 12]. Systematic reviews and meta-analyses assessing outcomes in patients undergoing hemodynamically supported PCI were examined to provide aggregated evidence on clinical efficacy and complications [13]. Comparative studies evaluating PCI versus optimal medical therapy were also reviewed to contextualize procedural decision-making and patient selection [15].

Key landmark clinical trials were included to inform procedural guidance and optimization strategies. The SYNTAX trial and its long-term follow-up were reviewed to assess outcomes of PCI in complex coronary artery disease and to support risk-based revascularization decisions [14]. The FAME trial was included to demonstrate the role of fractional flow reserve-guided PCI in improving clinical outcomes compared with angiography-guided strategies [9]. Additionally, studies evaluating antithrombotic strategies during PCI, such as the HORIZONS-AMI trial, were incorporated to assess peri-procedural pharmacologic optimization and its impact on ischemic and bleeding outcomes [10].

Preprocedural evaluation frameworks and contemporary perspectives on risk assessment before PCI were included to integrate clinical, anatomical, and procedural factors into comprehensive decision-making models [8]. Articles were screened for relevance based on predefined inclusion criteria: (1) focus on PCI risk stratification, (2) evaluation of peri-procedural optimization strategies, (3) reporting of clinical outcomes or prognostic implications, and (4) relevance to complex or high-risk PCI populations. Studies focusing exclusively on non-coronary interventions or lacking clinical outcome data were excluded.

Data extraction involved identifying study design, population characteristics, risk stratification tools, optimization strategies, and reported outcomes. Findings were synthesized qualitatively due to heterogeneity in study designs and outcome measures. Emphasis was placed on integrating evidence from multiple sources to identify consistent patterns, clinical implications, and gaps in knowledge. The review followed principles of narrative synthesis, highlighting mechanistic insights, clinical applicability, and evidence-based recommendations for improving outcomes in complex PCI.

This methodological approach aimed to provide a comprehensive and clinically relevant synthesis of current evidence on risk stratification and peri-procedural optimization, with the goal of informing clinicians, researchers, and guideline developers on strategies to enhance procedural success and patient outcomes.

3. Results

The synthesis of evidence demonstrates that risk stratification and peri-procedural optimization significantly influence clinical outcomes in patients undergoing complex percutaneous coronary interventions (PCI). Contemporary guideline-directed management emphasizes individualized patient assessment incorporating clinical, anatomical, and procedural factors to guide decision-making and improve procedural success while minimizing adverse events [1]. Across studies, multidimensional risk models consistently showed superior predictive performance compared with isolated clinical or angiographic parameters, underscoring the importance of integrated stratification frameworks in complex PCI.

Anatomical risk stratification using the SYNTAX score remains a cornerstone in assessing coronary lesion complexity and guiding revascularization strategies. Initial validation studies demonstrated that higher SYNTAX scores correlate with increased adverse cardiovascular outcomes, including mortality and repeat revascularization [3, 14]. Subsequent refinements incorporating clinical variables, such as the clinical SYNTAX score and SYNTAX score II, further improved prognostic accuracy and informed decision-making between PCI and coronary artery bypass grafting [4, 6]. Derived risk models have also shown predictive utility in stratifying patients undergoing PCI, particularly in high-risk cohorts with multivessel or left main coronary artery disease [5]. Emerging multi-risk score models integrating demographic, clinical, and procedural parameters have demonstrated improved prediction of long-term ischemic events, highlighting the evolving role of data-driven stratification tools [7].

Physiological lesion assessment using fractional flow reserve (FFR) has been shown to significantly improve outcomes by guiding lesion selection for intervention. In multivessel coronary artery disease, FFR-guided PCI reduced major adverse cardiac events compared with angiography-guided PCI, reinforcing the role of functional assessment in optimizing procedural strategy [9]. Additionally, advances in intracoronary imaging and procedural planning have been associated with enhanced stent deployment, reduced restenosis, and improved long-term outcomes, although these aspects require further integration into standardized risk algorithms.

Peri-procedural optimization strategies have been identified as critical determinants of procedural success and patient outcomes. Procedural factors such as vascular access, antithrombotic therapy, hemodynamic support, and operator experience significantly influence PCI outcomes [2]. Antithrombotic optimization, including the use of bivalirudin in acute myocardial infarction, has demonstrated reduced bleeding complications without compromising ischemic outcomes, emphasizing the importance of tailored pharmacotherapy [10].

Hemodynamic support devices have emerged as pivotal adjuncts in high-risk PCI, particularly in patients with severe left ventricular dysfunction, complex multivessel disease, or cardiogenic shock. Mechanical circulatory support devices, including Impella and intra-aortic balloon pump, have been associated with improved hemodynamic stability and procedural safety in selected populations [11, 12]. A recent systematic review and meta-analysis further suggested improved procedural outcomes and potential survival benefits in high-risk patients undergoing Impella-supported PCI, although heterogeneity among studies warrants cautious interpretation [13].

Comparative analyses between PCI and optimal medical therapy have demonstrated that while PCI provides symptomatic relief and improved quality of life in stable coronary artery disease, patient selection remains crucial to optimize clinical benefit and avoid unnecessary procedural risk [15]. These findings reinforce the need for comprehensive risk assessment before intervention, particularly in complex coronary anatomy or high-risk clinical profiles.

Preprocedural evaluation frameworks integrating clinical comorbidities, frailty, renal function, and left ventricular performance have been increasingly recognized as essential components of modern risk stratification. Contemporary perspectives highlight the importance of multidisciplinary heart team discussions and shared decision-making to align procedural strategies with patient-specific risk-benefit profiles [8]. Furthermore, guideline recommendations emphasize that procedural decisions should be guided by symptom burden, hemodynamic stability, and the presence of clinically significant ischemia or conduction abnormalities, rather than anatomical findings alone [1].

Collectively, the evidence indicates that a comprehensive, multimodal approach to risk stratification and peri-procedural optimization significantly improves outcomes in complex PCI. Integrating anatomical scores, physiological assessment, clinical risk models, and procedural optimization strategies allows for individualized treatment planning, enhanced procedural safety, and improved long-term cardiovascular outcomes. Continued refinement of predictive models and incorporation of emerging technologies are expected to further enhance precision in patient selection and procedural planning, ultimately improving survival and reducing complications in complex PCI populations.

4. Discussion

Risk stratification and peri-procedural optimization are central to improving outcomes in complex percutaneous coronary interventions (PCI), particularly in patients with multivessel coronary artery disease, high anatomical complexity, or significant comorbidities. Contemporary guidelines emphasize individualized decision-making based on anatomical, clinical, and procedural factors, underscoring the need for comprehensive risk assessment prior to revascularization [1]. Complex PCI is associated with increased procedural complications, higher rates of restenosis, and adverse cardiovascular outcomes, making structured risk assessment and optimization strategies essential components of modern interventional cardiology practice.

Anatomical risk assessment tools, particularly the SYNTAX score, have played a pivotal role in stratifying patients with complex coronary artery disease. The original SYNTAX score, introduced as an angiographic grading system, quantifies lesion complexity and has demonstrated prognostic value for long-term outcomes following PCI [3]. Subsequent refinements, including the clinical SYNTAX score and SYNTAX score II, incorporated clinical variables such as age, renal function, and left ventricular function to improve predictive accuracy and guide revascularization strategy selection between PCI and coronary artery bypass grafting (CABG) [4, 6]. Long-term follow-up from the SYNTAX trial further established the prognostic significance of anatomical complexity, with higher SYNTAX scores correlating with increased mortality and major adverse cardiovascular events [14]. These findings support the continued use of anatomical and clinical risk models to guide patient selection and procedural planning.

Beyond SYNTAX-based approaches, contemporary research has explored novel composite risk models integrating clinical, procedural, and laboratory parameters. A multiple risk score model developed by Qiu et al. [7] demonstrated improved prediction of long-term ischemic events following PCI, highlighting the growing emphasis on personalized risk prediction frameworks. Similarly, Yadav et al. [5] demonstrated that derived risk scores combining anatomical and clinical parameters outperform angiographic assessment alone, reinforcing the importance of multimodal risk stratification in complex PCI populations. These models are increasingly relevant in the era of precision medicine, where individualized risk prediction can guide procedural strategies and post-procedural management.

Peri-procedural optimization encompasses procedural techniques, pharmacotherapy, and hemodynamic support strategies aimed at minimizing complications and improving outcomes. Procedural factors such as vascular access site selection, lesion preparation, stent optimization, and intravascular imaging guidance significantly influence PCI outcomes. Patel et al., [2] emphasized that both procedural and nonprocedural factors contribute to PCI success, including operator experience, patient selection, and adherence to evidence-based pharmacotherapy. Advances in imaging modalities, such as fractional flow reserve (FFR), have also transformed PCI decision-making. The FAME study demonstrated that FFR-guided PCI improves clinical outcomes compared with angiography-guided strategies, particularly in

multivessel disease, by identifying functionally significant lesions requiring intervention [9]. These findings underscore the importance of physiology-guided revascularization in complex PCI settings.

Pharmacological optimization remains a cornerstone of peri-procedural management. Antithrombotic therapy, including the use of bivalirudin, has been shown to reduce bleeding complications and improve outcomes in acute myocardial infarction patients undergoing primary PCI, as demonstrated in the HORIZONS-AMI trial [10]. Current guidelines recommend individualized antiplatelet and anticoagulation strategies based on bleeding and ischemic risk profiles, further reinforcing the role of risk stratification in guiding therapy [1]. Optimal medical therapy before and after PCI, including statins, beta-blockers, and renin–angiotensin system inhibitors, is also essential to improve long-term outcomes, as highlighted in recent meta-analyses comparing PCI with optimal medical therapy in stable coronary artery disease [15].

High-risk PCI, particularly in patients with severe left ventricular dysfunction, cardiogenic shock, or complex multivessel disease, may require mechanical circulatory support. Hemodynamic support devices such as intra-aortic balloon pumps, Impella, and extracorporeal membrane oxygenation (ECMO) have been increasingly utilized to stabilize patients during complex procedures. Simonton and Basir [11] emphasized the role of hemodynamic support in improving procedural safety and enabling complete revascularization in high-risk patients. Recent reviews and meta-analyses have further demonstrated improved procedural success and hemodynamic stability with Impella-supported PCI, although the impact on long-term mortality remains an area of ongoing investigation [12, 13]. These findings highlight the importance of careful patient selection and risk–benefit assessment when considering mechanical circulatory support.

Preprocedural evaluation plays a crucial role in optimizing outcomes in complex PCI. Comprehensive assessment of comorbidities, frailty, renal function, and bleeding risk is essential to tailor procedural strategies and pharmacotherapy. Haddad and Cairns [8] emphasized that structured preprocedural evaluation improves procedural planning and risk mitigation. Additionally, shared decision-making informed by validated risk models aligns with contemporary guideline recommendations, promoting patient-centered care and optimizing clinical outcomes [1]. The integration of clinical, anatomical, and physiological data enables interventional cardiologists to stratify risk more accurately and personalize procedural strategies.

5. Conclusion

Despite significant advancements, challenges remain in risk stratification and peri-procedural optimization. Many existing risk models were developed in selected trial populations and may not fully capture real-world complexity, particularly in elderly patients, those with multiple comorbidities, or patients undergoing complex lesion subsets such as chronic total occlusions and left main disease. Furthermore, the rapid evolution of PCI techniques, devices, and pharmacotherapies necessitates continuous validation and updating of risk models to maintain clinical relevance. Emerging machine learning–based risk prediction tools may offer improved accuracy and adaptability but require prospective validation before widespread clinical implementation.

Another important consideration is the balance between ischemic and bleeding risks. Aggressive revascularization and antithrombotic therapy can reduce ischemic events but may increase bleeding complications, particularly in high-risk populations. Individualized risk stratification tools are therefore essential to guide therapeutic intensity and minimize adverse outcomes. Moreover, procedural volume and operator expertise significantly influence outcomes in complex PCI, emphasizing the need for specialized centers and experienced operators for high-risk cases.

Article Information

Disclaimer (Artificial Intelligence): The author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.), and text-to-image generators have been used during writing or editing of manuscripts.

Competing Interests: Authors have declared that no competing interests exist.

References

[1] J. S. Lawton, J. E. Tamis-Holland, S. Bangalore, E. R. Bates, T. M. Beckie, J. M. Bischoff, J. A. Bittl, M. G. Cohen, J. M. DiMaio, C. W. Don, S. E. Fremes, M. F. Gaudino, Z. D. Goldberger, M. C. Grant, J. B. Jaswal, P. A. Kurlansky, R. Mehran, T. S. J. Metkus, L. C. Nnacheta, S. V. Rao, F. W. Sellke, G. Sharma, C. M. Yong, and B. A. Zwischenberger. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 145(3):e18–e114, 2022. URL https://doi.org/10.1161/CIR.0000000000001038.

[2] D. B. Patel, R. Shah, and I. S. Jovin. Improving outcomes of percutaneous coronary interventions in patients with stable ischemic heart disease. *Journal of Thoracic Disease*, 12(4):1740–1749, 2020. URL https://doi.org/10.21037/jtd.2019.11.17.

[3] G. Sianos, M. A. Morel, A. P. Kappetein, M. C. Morice, A. Colombo, K. Dawkins, and P. W. Serruys. The SYNTAX score: An angiographic tool grading the complexity of coronary artery disease. *Euro Intervention*, 1(2):219–227, 2005. URL https://www.academia.edu/download/51845706/sintax_20score_20sobre_20pci.pdf.

[4] S. Garg, G. Sarno, H. M. Garcia-Garcia, C. Girasis, J. J. Wykrzykowska, G. A. van Es, K.D Dawkins, and P. W. Serruys. A new tool for the risk stratification of patients with complex coronary artery disease: The clinical SYNTAX score. *Circulation: Cardiovascular Interventions*, 3(4):317–326, 2010. URL https://doi.org/10.1161/CIRCINTERVENTIONS.109.914051.

[5] M. Yadav, T. Palmerini, A. Caixeta, M. V. Madhavan, and G. W. Stone. Prediction of coronary risk by SYNTAX and derived scores. *Journal of the American College of Cardiology*, 62(14):1219–1230, 2013. URL https://doi.org/10.1016/j.jacc.2013.06.047.

[6] V. Farooq, D. Van Klaveren, and E. W. Steyerberg. Clinical and angiographic risk models to guide decision-making between PCI and CABG: The SYNTAX score II. *European Heart Journal*, 32(16):1994–2002, 2011. URL https://doi.org/10.1016/S0140-6736(13)60108-7.

[7] M. Qiu, X. Liu, and H Zhang. A novel multiple risk score model for predicting long-term ischemic events in patients undergoing PCI. *Frontiers in Cardiovascular Medicine*, 9, 2022. URL https://doi.org/10.3389/fcvm.2022.756379.

[8] K. Haddad and J. A. Cairns. Preprocedural evaluation and risk stratification before percutaneous coronary intervention: Current perspectives. *Canadian Journal of Cardiology*, 2025. URL https://doi.org/10.1016/j.cjca.2025.06.005.

[9] P. A. L. Tonino, B. De Bruyne, N. H. J. Pijls, U. Siebert, F. Ikeno, M. van 't Veer, V. Klauss, G. Manoharan, T. Engstrøm, K. G. Oldroyd, P. N. Ver Lee, P. A. MacCarthy, W. F. Fearon, and FAME Study Investigators. Fractional flow reserve versus angiography for guiding PCI in multivessel coronary artery disease. *New England Journal of Medicine*, 360(3):213–224, 2009. URL https://doi.org/10.1056/NEJMoa0807611.

[10] G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, G. Dangas, S. Chiu Wong, A. J. Kirtane, H. Parise, and R. Mehran. Bivalirudin during primary PCI in acute myocardial infarction. *New England Journal of Medicine*, 358(21):2218–2230, 2008. URL https://doi.org/10.1056/NEJMoa0708191.

[11] C. A. Simonton and M. B. Basir. The role of hemodynamic support in high-risk percutaneous coronary intervention. *US Cardiology Review*, 14(1):1–8, 2020. URL https://doi.org/10.15420/usc.2019.19.

[12] V. S. M. Gogineni and N. K. Kapur. High-risk percutaneous coronary intervention. *Cardiovascular Innovations and Applications*, 9(2):105–118, 2024. URL https://doi.org/10.15212/CVIA.2024.0020.

[13] G. Di Pietro, R. Improtaa, O. De Filippob, F. Brunob, L. I. Birtoloa, R. Colantonioa, A. Gaspardonec, F. Tomaid, G. Sardellaa, F. D'Ascenzob, and M. Mancone. Systematic review and meta-analysis of outcomes in high-risk patients undergoing Impella-supported PCI. *American Journal of Cardiology. Advance online publication*, 2025. URL https://doi.org/10.1016/j.amjcard.2025.09.008.

[14] P. W. Serruys, Y. Onuma, S. Garg, G. Sarno, M. van den Brand, and M. A. Morel. Five-year clinical outcomes of the SYNTAX trial. *The Lancet*, 373(9667):1190–1199, 2009. URL https://doi.org/10.1016/S0140-6736(09)60325-7.

[15] A. Shah, W. U. Khan, M. Aamir, D. Jan, H. Usman, A. A. Khan, F. Ullah, and S. Muhammad. Comparative effectiveness of PCI versus optimal medical therapy in stable coronary artery disease: A systematic review and meta-analysis. *European Journal of Cardiovascular Medicine*, 15(11):247–264, 2025.